International journal of clinical oncologyHumansFemaleUterine Cervical NeoplasmsImmune Checkpoint InhibitorsMiddle Aged
Real-world multicenter study of immune checkpoint inhibitors in advanced cervical cancer across HPV-associated and HPV-independent subtypes.
Kazuhiro Ko, Mayu Fukuda, Koji Yamanoi, Nobutaka Hayashi, Hisateru Yasui, Takuma Hayashi, Yoshihiro Yakushijin, Takehiko Tsumura, Atsushi Shirakawa, Chiho Nakashima, Yoshinori Imamura, Chikako Yamauchi, Toshio Shimizu, Takahito Ashihara, Nobuhiro Shibata
Published: 202610.1007/s10147-025-02924-w
Abstract
BACKGROUND: Cervical cancer remains a major health problem, and HPV-independent subtypes such as gastric-type adenocarcinoma carry dismal outcomes. Although immune checkpoint inhibitors (ICIs) have improved survival in large trials, their real-world…
Preview only. Read the full abstract at the source